[
  {
    "ts": null,
    "headline": "Viatris Inc. stock rises Tuesday, outperforms market",
    "summary": "Viatris Inc. stock rises Tuesday, outperforms market",
    "url": "https://finnhub.io/api/news?id=a93996a7a544b5d5660473b4f2bb5dcd8f61d5b7b896de11cbcd3a9301d039a9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742318340,
      "headline": "Viatris Inc. stock rises Tuesday, outperforms market",
      "id": 133258316,
      "image": "",
      "related": "VTRS",
      "source": "MarketWatch",
      "summary": "Viatris Inc. stock rises Tuesday, outperforms market",
      "url": "https://finnhub.io/api/news?id=a93996a7a544b5d5660473b4f2bb5dcd8f61d5b7b896de11cbcd3a9301d039a9"
    }
  },
  {
    "ts": null,
    "headline": "VTRS Investigation: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS",
    "summary": "NEW YORK, March 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor...",
    "url": "https://finnhub.io/api/news?id=16f80a90aa8fb8f66315ce8f1d55ab3fcb595de4e85439df551e25be8fc94e01",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742304485,
      "headline": "VTRS Investigation: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS",
      "id": 133230769,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "NEW YORK, March 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor...",
      "url": "https://finnhub.io/api/news?id=16f80a90aa8fb8f66315ce8f1d55ab3fcb595de4e85439df551e25be8fc94e01"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco (NYSE:ELAN).",
    "url": "https://finnhub.io/api/news?id=6ebeca7ae27a4266f203e5748303d94f9e9622104bc9217b2c514eea493340fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742288480,
      "headline": "Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment",
      "id": 133317323,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco (NYSE:ELAN).",
      "url": "https://finnhub.io/api/news?id=6ebeca7ae27a4266f203e5748303d94f9e9622104bc9217b2c514eea493340fa"
    }
  }
]